Rockwell Medical, Inc. (RMTI) News

Rockwell Medical, Inc. (RMTI): $1.60

0.03 (+1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RMTI News Items

RMTI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RMTI News Highlights

  • RMTI's 30 day story count now stands at 2.
  • Over the past 1 day, the trend for RMTI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RMTI News From Around the Web

Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the Rockwell Medical websi

Yahoo | February 15, 2022

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant

Yahoo | February 14, 2022

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea

Two product forms of Triferic® are now approved in South KoreaWIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyr

Yahoo | January 20, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

Analysts’ Top Healthcare Picks: Rockwell Med (RMTI), Biogen (BIIB)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTI – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Rockwell Med (RMTI) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company's shares closed last Friday at $0.47, close to its 52-week low of $0.34. According to TipRanks.

Christine Brown on TipRanks | January 18, 2022

The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

VANCOUVER, BC / ACCESSWIRE / January 14, 2022 / The Power Play by The Market Herald has announced the release of new interviews with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical discussing their latest press releases.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Yahoo | January 14, 2022

Rockwell Medical Shares Surge On South Korean Approval For Iron Supplementation Therapy

Rockwell Medical Inc''s (NASDAQ: RMTI ) partner, Jeil Pharmaceutical Co Ltd , has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea. Regarding the license, Rockwell Full story available on Benzinga.com

Benzinga | January 13, 2022

Rockwell Medical jumps 17% on regulatory approval of Triferic Ijection in South Korea

Rockwell Medical (RMTI) soars 17.4% premarket after its partner, Jeil Pharmaceutical Co., Ltd., received regulatory approval for Triferic Injection (ferric pyrophosphate citrate

Seeking Alpha | January 13, 2022

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea

-Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia manag

Yahoo | January 13, 2022

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference

WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference. The presentation will become publicly available for on-demand listening be

Yahoo | January 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.429 seconds.